Pharmaceutical

ASCO 2024: Tagrisso approaches standard of Care status for NSCLC

At the ASCO annual meeting, Tagrisso showed an improvement in progression free survival compared to placebo.

Jun 4, 2024 - 04:00
ASCO 2024: Tagrisso approaches standard of Care status for NSCLC
At the ASCO annual meeting, Tagrisso showed an improvement in progression free survival compared to placebo.
Read the original article

Tags:

Previous Article

ASCO 2024: American Cancer Society and ASCO combine cancer resource websites

Next Article

Lilly strikes deal with QurAlis for preclinical ALS candidate

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA delays enforcement of a pharmaceutical supply chain law to stop counterfeit drugs

STAT+: FDA delays enforcement of a pharmaceutical suppl...

Aug 29, 2023

STAT+: A sweeping new lawsuit against J&J asks: Are employers liable if they overpay for drugs?

STAT+: A sweeping new lawsuit against J&J asks: Are emp...

Feb 5, 2024

Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis

Diabetes duration has minimal impact on SGLT2 inhibitor...

Sep 2, 2024